Literature DB >> 23666674

Impaired contractile function due to decreased cardiac myosin binding protein C content in the sarcomere.

Y Cheng1, X Wan, T A McElfresh, X Chen, K S Gresham, D S Rosenbaum, M P Chandler, J E Stelzer.   

Abstract

Mutations in cardiac myosin binding protein C (MyBP-C) are a common cause of familial hypertrophic cardiomyopathy (FHC). The majority of MyBP-C mutations are expected to reduce MyBP-C expression; however, the consequences of MyBP-C deficiency on the regulation of myofilament function, Ca²⁺ homeostasis, and in vivo cardiac function are unknown. To elucidate the effects of decreased MyBP-C expression on cardiac function, we employed MyBP-C heterozygous null (MyBP-C+/-) mice presenting decreases in MyBP-C expression (32%) similar to those of FHC patients carrying MyBP-C mutations. The levels of MyBP-C phosphorylation were reduced 53% in MyBP-C+/- hearts compared with wild-type hearts. Skinned myocardium isolated from MyBP-C+/- hearts displayed decreased cross-bridge stiffness at half-maximal Ca²⁺ activations, increased steady-state force generation, and accelerated rates of cross-bridge recruitment at low Ca²⁺ activations (<15% and <25% of maximum, respectively). Protein kinase A treatment abolished basal differences in rates of cross-bridge recruitment between MyBP-C+/- and wild-type myocardium. Intact ventricular myocytes from MyBP-C+/- hearts displayed abnormal sarcomere shortening but unchanged Ca²⁺ transient kinetics. Despite a lack of left ventricular hypertrophy, MyBP-C+/- hearts exhibited elevated end-diastolic pressure and decreased peak rate of LV pressure rise, which was normalized following dobutamine infusion. Furthermore, electrocardiogram recordings in conscious MyBP-C+/- mice revealed prolonged QRS and QT intervals, which are known risk factors for cardiac arrhythmia. Collectively, our data show that reduced MyBP-C expression and phosphorylation in the sarcomere result in myofilament dysfunction, contributing to contractile dysfunction that precedes compensatory adaptations in Ca²⁺ handling, and chamber remodeling. Perturbations in mechanical and electrical activity in MyBP-C+/- mice could increase their susceptibility to cardiac dysfunction and arrhythmia.

Entities:  

Keywords:  cardiomyopathy; contractile function; cross-bridge kinetics; myocardium; myosin binding protein C

Mesh:

Substances:

Year:  2013        PMID: 23666674      PMCID: PMC3727108          DOI: 10.1152/ajpheart.00929.2012

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  62 in total

1.  Cardiac myosin binding protein C and its phosphorylation regulate multiple steps in the cross-bridge cycle of muscle contraction.

Authors:  Arthur T Coulton; Julian E Stelzer
Journal:  Biochemistry       Date:  2012-04-06       Impact factor: 3.162

2.  Ablation of cardiac myosin-binding protein-C accelerates stretch activation in murine skinned myocardium.

Authors:  Julian E Stelzer; Sandy B Dunning; Richard L Moss
Journal:  Circ Res       Date:  2006-03-30       Impact factor: 17.367

3.  Roles for cardiac MyBP-C in maintaining myofilament lattice rigidity and prolonging myosin cross-bridge lifetime.

Authors:  Bradley M Palmer; Sakthivel Sadayappan; Yuan Wang; Abbey E Weith; Michael J Previs; Tanya Bekyarova; Thomas C Irving; Jeffrey Robbins; David W Maughan
Journal:  Biophys J       Date:  2011-10-05       Impact factor: 4.033

Review 4.  Electromechanical coupling in the cardiac myocyte; stretch-arrhythmia feedback.

Authors:  Henk E D J ter Keurs
Journal:  Pflugers Arch       Date:  2011-03-04       Impact factor: 3.657

5.  Cardiac myosin binding protein C insufficiency leads to early onset of mechanical dysfunction.

Authors:  Candida L Desjardins; Yong Chen; Arthur T Coulton; Brian D Hoit; Xin Yu; Julian E Stelzer
Journal:  Circ Cardiovasc Imaging       Date:  2011-12-07       Impact factor: 7.792

Review 6.  Signaling and myosin-binding protein C.

Authors:  Jeanne James; Jeffrey Robbins
Journal:  J Biol Chem       Date:  2011-01-21       Impact factor: 5.157

7.  The new HNO donor, 1-nitrosocyclohexyl acetate, increases contractile force in normal and β-adrenergically desensitized ventricular myocytes.

Authors:  Ali El-Armouche; Azadeh Wahab; Katrin Wittköpper; Thomas Schulze; Felix Böttcher; Lutz Pohlmann; S Bruce King; Jenna F DuMond; Christian Gerloff; Rainer H Böger; Thomas Eschenhagen; Lucie Carrier; Sonia Donzelli
Journal:  Biochem Biophys Res Commun       Date:  2010-10-12       Impact factor: 3.575

8.  Contractile dysfunction irrespective of the mutant protein in human hypertrophic cardiomyopathy with normal systolic function.

Authors:  Sabine J van Dijk; E Rosalie Paalberends; Aref Najafi; Michelle Michels; Sakthivel Sadayappan; Lucie Carrier; Nicky M Boontje; Diederik W D Kuster; Marjon van Slegtenhorst; Dennis Dooijes; Cris dos Remedios; Folkert J ten Cate; Ger J M Stienen; Jolanda van der Velden
Journal:  Circ Heart Fail       Date:  2011-12-16       Impact factor: 8.790

Review 9.  Identifying sarcomere gene mutations in hypertrophic cardiomyopathy: a personal history.

Authors:  Christine E Seidman; J G Seidman
Journal:  Circ Res       Date:  2011-03-18       Impact factor: 17.367

Review 10.  Increased myofilament Ca2+-sensitivity and arrhythmia susceptibility.

Authors:  Sabine Huke; Björn C Knollmann
Journal:  J Mol Cell Cardiol       Date:  2010-01-22       Impact factor: 5.000

View more
  24 in total

Review 1.  The genetic basis of hypertrophic cardiomyopathy in cats and humans.

Authors:  Mark D Kittleson; Kathryn M Meurs; Samantha P Harris
Journal:  J Vet Cardiol       Date:  2015-12       Impact factor: 1.701

2.  Phosphorylation of cardiac myosin-binding protein-C contributes to calcium homeostasis.

Authors:  Mohit Kumar; Kobra Haghighi; Evangelia G Kranias; Sakthivel Sadayappan
Journal:  J Biol Chem       Date:  2020-06-18       Impact factor: 5.157

3.  The contribution of cardiac myosin binding protein-c Ser282 phosphorylation to the rate of force generation and in vivo cardiac contractility.

Authors:  Kenneth S Gresham; Ranganath Mamidi; Julian E Stelzer
Journal:  J Physiol       Date:  2014-06-20       Impact factor: 5.182

4.  Doxorubicin-induced carbonylation and degradation of cardiac myosin binding protein C promote cardiotoxicity.

Authors:  Baikuntha Aryal; Jinsook Jeong; V Ashutosh Rao
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-21       Impact factor: 11.205

5.  Molecular effects of the myosin activator omecamtiv mecarbil on contractile properties of skinned myocardium lacking cardiac myosin binding protein-C.

Authors:  Ranganath Mamidi; Kenneth S Gresham; Amy Li; Cristobal G dos Remedios; Julian E Stelzer
Journal:  J Mol Cell Cardiol       Date:  2015-06-20       Impact factor: 5.000

6.  Sarcomeric protein modification during adrenergic stress enhances cross-bridge kinetics and cardiac output.

Authors:  Kenneth S Gresham; Ranganath Mamidi; Jiayang Li; Hyerin Kwak; Julian E Stelzer
Journal:  J Appl Physiol (1985)       Date:  2016-12-01

7.  Cardiac myosin binding protein-C: a novel sarcomeric target for gene therapy.

Authors:  Ranganath Mamidi; Jiayang Li; Kenneth S Gresham; Julian E Stelzer
Journal:  Pflugers Arch       Date:  2013-12-06       Impact factor: 3.657

Review 8.  Strategies for targeting the cardiac sarcomere: avenues for novel drug discovery.

Authors:  Joshua B Holmes; Chang Yoon Doh; Ranganath Mamidi; Jiayang Li; Julian E Stelzer
Journal:  Expert Opin Drug Discov       Date:  2020-02-18       Impact factor: 6.098

9.  Sarcomere-based genetic enhancement of systolic cardiac function in a murine model of dilated cardiomyopathy.

Authors:  Jiayang Li; Kenneth S Gresham; Ranganath Mamidi; Chang Yoon Doh; Xiaoping Wan; Isabelle Deschenes; Julian E Stelzer
Journal:  Int J Cardiol       Date:  2018-09-21       Impact factor: 4.164

10.  Contractile dysfunction in a mouse model expressing a heterozygous MYBPC3 mutation associated with hypertrophic cardiomyopathy.

Authors:  David Barefield; Mohit Kumar; Pieter P de Tombe; Sakthivel Sadayappan
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-01-24       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.